Shreehas Tambe appointed CEO & Managing Director of Biocon
Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited
Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited
Otsuka will pay $700 million to Transcend shareholders at closing, with an additional $525 million in contingent payments tied to future sales milestones
STADA will market and distribute two EMA approved biosimilars developed by CuraTeQ in select European Union territories
TERN-701, a next-generation therapy targeting chronic myeloid leukemia (CML), a form of blood cancer that still presents treatment challenges despite decades of advances
SNV4818, the oral drug, is pan-mutant–selective PI3K? inhibitor aimed at treating HR+/HER2- breast cancer and potentially other solid tumors
The initial consideration for the transaction is US$ 12 million
These upgrades will enable advanced development and flexible manufacturing, supporting complex therapeutics and meeting global demand for advanced pharmaceutical solutions
Desidustat tablets are a novel oral HIF-PHI approved for treating anaemia in non-dialysis adult CKD patients
Subscribe To Our Newsletter & Stay Updated